logo-loader

ProMetic confident IPF drug will outperform current treatments after trial

Published: 08:31 22 Feb 2017 EST

picture of lungs
ProMetic is upbeat after phase II trial

ProMetic Life Sciences Inc’s (TSX:PLI) dosing trial of its idiopathic pulmonary fibrosis treatment PBI-4050 has confirmed early indications of benefit reported in November.

"PBI-4050, either used alone or in Combi-1, demonstrated very promising early indications of efficacy, considering that current drugs approved for IPF only slow (but do not reverse) the decline in lung respiratory function", said John Moran, Prometic’s chief medical officer. 

"It is also important to note that during our clinical trial, there were no deaths nor did we see any subjects experiencing a decrease in FVC [how much someone can exhale] of 10% or more, contrary to the outcomes in the other IPF trials.”

In addition to demonstrating that the drug was safe and very well tolerated, an endpoint for the trial was to show there was benefit from its prescription either alone or in combination with nintedanib or pirfenidone, the drugs currently prescribed for IPF.

Pierre Laurin, ProMetic's chief executive, added the results supported the rationale and clinical study design for the Phase 2/3 IPF clinical trial due to start in the second quarter.

“We expect to see PBI-4050, alone or in combination with one of the commercially approved IPF drugs, continue to outperform the current drugs in terms of efficacy, safety and tolerability".

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

1 hour, 49 minutes ago